Gastroesophageal reflux disease (GERD) is a very common disease, as about a quarter of the Western population has GERD symptoms at least weekly and GERD is the most frequent reason for outpatient gastroenterology consultation. GERD treatment is based on proton pump inhibitor (PPI) use, but PPI may be ineffective in some patients and potentially unsafe if administered for very long time. A new medical compound (Marial®) has been introduced on the Italian market. This product contains magnesium alginate and a phytopolymer: it may be able to repair ulcer/erosion, protect mucosal tissue, and contrast acid contents. The current survey was conducted on a large group of GERD patients visited at 56 Italian gastroenterological offices. Patients were treated with PPI alone, PPI plus add-on, or Marial® for 4 weeks: the choice was decided by each gastroenterologist on the basis of the best practice criterion. A reflux symptoms index (RSI) questionnaire was used to weekly assess the clinical features. Marial® and PPI plus add-on significantly reduced RSI scores, from the second week. Noteworthy, Marial® was more effective than PPI plus add-on. In conclusion, the current survey demonstrated that patients with GERD perceived a significant improvement of GERD symptoms measured by the RSI questionnaire. Marial® was as effective as PPI plus add-on.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Eosinophilic esophagitis].
Inn Med (Heidelb)
January 2025
Service de gastro-entérologie et d'hepatologie, Centre hospitalier universitaire vaudois (CHUV), Lausanne, Schweiz.
Eosinophilic esophagitis (EoE) was first described in the early 1990s. Initially a rarity, it is now the most common cause of dysphagia for solid foods in young adults. Its prevalence is estimated to be 1:2000.
View Article and Find Full Text PDFEfficacy of Baclofen as Add-on Therapy for Refractory Gastroesophageal Reflux Disease: A Meta-analysis.
J Clin Gastroenterol
June 2024
Department of General Surgery, Xiong'an Xuanwu Hospital, Xiong'an, Hebei Province, China.
Objectives: As a GABAB receptor agonist, baclofen has demonstrated efficacy in alleviating symptoms of refractory gastroesophageal reflux disease (r-GERD). This meta-analysis aims to evaluate the safety and effectiveness of baclofen as an add-on therapy for this condition.
Method: We conducted a comprehensive search of the PubMed, Embase, and Web of Science databases for studies published up until October 2023.
The Scope of Pre- and Probiotics as an Add-on to Proton-pump Inhibitors in Various Clinical Indications.
J Assoc Physicians India
December 2023
Consultant, Department of Gastroenterology, North Bengal Hospital, Kolkata, West Bengal, India.
Article Synopsis
- - The study aimed to analyze the usage patterns of proton-pump inhibitors (PPIs) in prescriptions and to promote evidence-based recommendations for incorporating probiotics alongside PPIs for various gastrointestinal conditions.
- - A survey of 1,007 healthcare professionals revealed that over 43% believed 10-30% of patients were on long-term PPI therapy, with most often prescribing PPIs for GERD-related gastritis and peptic ulcers; 91% noted that long-term PPI use disrupts gut flora.
- - The findings highlighted a strong consensus among healthcare professionals (85%) on the benefits of prescribing probiotics to prevent gastrointestinal issues linked to PPI use, emphasizing a trend towards co-prescription to enhance patient health.
The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease.
Prz Gastroenterol
December 2023
Department of Pharmacology, Medical University of Wroclaw, Wroclaw, Poland.
Introduction: The primary objective was to demonstrate the efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor (PPI) in the treatment of gastroesophageal reflux disease.
Aim: Reflux disease affects the largest percentage of the population worldwide, symptoms overlap with many other conditions which hamper diagnostic and therapy presenting challenges in treating patients and prompting an intensive search for new, more effective therapeutic regimens.
Material And Methods: A retrospective study was undertaken with 140 enrolled patients with reflux disease, confirmed by 24-hour pH impedance previously treated with PPIs without any significant improvement.
Multicentre prospective study to evaluate effectiveness and safety of gel-forming and hyaluronic-acid containing chewable tablets as add-on treatment in patients with gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor therapy.
BMC Gastroenterol
September 2023
G. Pohl-Boskamp GmbH & Co. KG, 25551, Hohenlockstedt, Germany.
Background: Gastroesophageal reflux disease (GERD) is a common disease which in the majority of patients is treated with proton pump inhibitors (PPI). However, up to 45% of the patients remain symptomatic on a standard dose of PPI. This study investigated the effectiveness and safety of an add-on therapy with the gel-forming chewable tablet Sobrade® in patients unsatisfied with PPI treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!